Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies
Sign Up to like & getrecommendations! Published in 2020 at "Diabetes Therapy"
DOI: 10.1007/s13300-020-00910-1
Abstract: This analysis evaluated the efficacy and safety of dulaglutide in Chinese patients with type 2 diabetes (T2D) aged ≥ 60 and read more here.
Keywords: efficacy safety; age; analysis; years years ... See more keywords
Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes Therapy"
DOI: 10.1007/s13300-021-01140-9
Abstract: Gastrointestinal (GI) events are the most frequent treatment-emergent adverse events (TEAEs) reported for glucagon-like peptide-1 receptor agonist therapies. This post hoc analysis of the AWARD-11 phase 3 trial assessed the GI tolerability of dulaglutide at… read more here.
Keywords: analysis; treatment; tolerability; vomiting diarrhea ... See more keywords
Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate‐to‐severe chronic kidney disease (AWARD‐7)
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.1111/dom.13668
Abstract: In patients with type 2 dibetes and moderate‐to‐severe chronic kidney disease, dulaglutide treatment led to body weight (BW) loss and lesser eGFR decline compared to insulin glargine. As BW may affect muscle mass, creatinine‐based eGFR… read more here.
Keywords: egfr; chronic kidney; dulaglutide; severe chronic ... See more keywords
Effect of once-weekly dulaglutide on renal function in patients with chronic kidney disease
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0273004
Abstract: Background Dulaglutide is associated with improved cardiovascular and kidney outcomes and can be a good therapeutic option for patients with type 2 diabetes with chronic kidney disease (CKD). In this study, the effects of dulaglutide… read more here.
Keywords: use dulaglutide; chronic kidney; dulaglutide; kidney disease ... See more keywords
Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy"
DOI: 10.2147/dmso.s134960
Abstract: Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist, which has been on the market in the USA since 2014. Dulaglutide has performed well in head-to-head studies against metformin, glargine, and sitagliptin, where its A1c lowering… read more here.
Keywords: profile weekly; efficacy safety; safety profile; dulaglutide ... See more keywords
A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of comparative effectiveness research"
DOI: 10.2217/cer-2018-0073
Abstract: AIM The prevalence of Type 2 diabetes in Canada is estimated to be 7.6% and rising. Given the substantial economic burden associated with Type 2 diabetes treatment, optimizing healthcare expenditure is extremely important. In the… read more here.
Keywords: analysis; insulin glargine; type diabetes; dulaglutide ... See more keywords
949-P: Dulaglutide Improves Kidney Fibrosis Biomarker Levels in Patients with Type 2 Diabetes and Moderate-to-Severe Chronic Kidney Disease
Sign Up to like & getrecommendations! Published in 2020 at "Diabetes"
DOI: 10.2337/db20-949-p
Abstract: The AWARD-7 clinical trial demonstrated that once-weekly dulaglutide slowed the decline in estimated glomerular filtration rate (eGFR) and decreased urine albumin/creatinine ratio compared to insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic… read more here.
Keywords: lilly company; eli lilly; type diabetes; self ... See more keywords
Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes Care"
DOI: 10.2337/dc20-1473
Abstract: OBJECTIVE To compare efficacy and safety of dulaglutide at doses of 3.0 and 4.5 mg versus 1.5 mg in patients with type 2 diabetes inadequately controlled with metformin. RESEARCH DESIGN AND METHODS Patients were randomly… read more here.
Keywords: patients type; treatment; efficacy; type diabetes ... See more keywords